A New Class of Precision Therapeutics that Inhibit Prostate Cancer Mediated Bone Destruction

Fangfang Qiao, Ryan R. Gordon, Abhinandan Pattanayak, Wenqi Li, Jaclyn Knibbe-Hollinger, Katelyn O’Neill, Weining Chen, Prathap Reddy Mukthapuram, Amarnath Natarajan, Raymond C. BerganbioRxiv 2025 · DOI

Abstract

Cancer mediated bone destruction remains a common cause of morbidity and mortality. Here we couple an inhibitor of cell movement to bone trophic bisphosphonates, forming heterobifunctional compounds termed Dual Acting Bone Defender agents (DABDs). DABDs inhibit prostate cancer cell motility and osteoclast mediated bone destruction in vitro. Our lead compound, BTE-EN1, inhibits circulating human prostate cancer cells from forming bone destructive lesions in mice and prolongs life in a dose-dependent fashion. In mice with established metastatic lesions, BTE-EN1 significantly decreases bone destruction by over 60% compared to the control. Mechanistically, BTE-EN1 binds hydroxyapatite, inhibits prenylation of Rap1A, induces apoptosis in osteoclasts, and inhibits Raf1 activation and formation of bone resorptive cavities in osteoclasts, thus retaining the function of its constituent chemicals. BTE-EN1 is not toxic to mice at doses 4,000-fold over those required for efficacy, exhibits anti-cell motility activity across other bone-destructive cancer cell types, and does not interfere with standard-of-care hormone therapy or chemotherapy. BTE-EN1 is a new class of highly active therapeutics that inhibit cancer mediated bone destruction and holds high potential for translation into humans.

Introduction: Breaking the Vicious Cycle

Prostate cancer (PCa) frequently metastasizes to the bone, initiating a "vicious cycle" of destruction. In this cycle, cancer cells stimulate osteoclasts to break down bone, which releases growth factors that further fuel tumor progression. While current treatments like bisphosphonates (e.g., alendronate) or RANKL inhibitors exist, they often suffer from limited efficacy and severe side effects, such as osteonecrosis of the jaw.

A major hurdle in treating established metastases has been drug delivery and retention. Precision motility inhibitors like KBU2046 show promise but have short systemic half-lives, preventing them from maintaining effective concentrations at the bone site. To overcome this, researchers developed Dual Acting Bone Defender agents (DABDs)—a new class of heterobifunctional drugs that "anchor" a motility inhibitor directly to the bone.

Engineering and Design of DABDs

The core innovation lies in the chemical linkage of the motility inhibitor KBU2046 to bone-seeking bisphosphonates. KBU2046 selectively inhibits Raf1 phosphorylation, stopping cell movement without direct cytotoxicity. By tethering it to alendronate or zoledronate, the researchers created a molecule that naturally homes to and remains in bone tissue.

Chemical structures of alendronic acid and zoledronic acid linked compounds (DABDs).

The synthesis involved testing various linker lengths to optimize biological activity. The lead compound, BTE-EN1, utilizes an alendronate anchor and was selected for its superior balance of potency and safety in vivo.

In Vitro Efficacy and Mechanism

DABDs were screened for their ability to bind hydroxyapatite (the primary mineral in bone) and inhibit biological processes essential for metastasis. As shown in Figure 5, these compounds significantly inhibited osteoclast-mediated bone resorption and cancer cell migration.

In vitro evaluation of DABDs showing inhibition of bone resorption (a-c) and cancer cell migration/invasion (d-f).

Mechanistic studies confirmed that BTE-EN1 retains the dual functionality of its parent molecules:

  1. Bisphosphonate Activity: It inhibits Rap1A prenylation, a hallmark of bisphosphonate action that induces osteoclast apoptosis.
  2. Motility Inhibition: It inhibits Raf1 activation (phosphorylation at Ser338), which freezes the actin-mediated movement required for osteoclasts to create resorptive cavities.

In Vivo Performance and Safety

The therapeutic potential of BTE-EN1 was validated in two mouse models of prostate cancer metastasis. In a prevention model (intracardiac injection), high-dose BTE-EN1 treatment resulted in 100% survival at 28 days, compared to 50% in the control group.

More importantly, in a state-of-the-art model of established metastasis (intra-caudal artery injection), BTE-EN1 reduced bone destruction by 62%. Quantitative Micro-CT and bioluminescent tracking confirmed that the drug effectively halted the progression of existing lesions.

Crucially, BTE-EN1 demonstrated an exceptional safety profile. It showed no systemic toxicity even at doses 4,000-fold higher than the effective therapeutic dose. Furthermore, it did not interfere with standard-of-care treatments like docetaxel or enzalutamide, and notably did not cause the jaw-specific bone loss often associated with traditional bisphosphonate therapy.

Conclusion

BTE-EN1 represents a significant advancement in precision oncology. By using bone-trophic molecules as anchors for motility inhibitors, this "dual-acting" approach successfully breaks the cycle of cancer-mediated bone destruction. With its high potency, broad activity across multiple cancer types (including lung and breast), and massive therapeutic window, BTE-EN1 is a strong candidate for clinical translation to improve the lives of patients with metastatic bone disease.

Summary updated

Abstract

Abstract Cancer mediated bone destruction remains a common cause of morbidity and mortality. Here we couple an inhibitor of cell movement to bone trophic bisphosphonates, forming heterobifunctional compounds termed Dual Acting Bone Defender agents (DABDs). DABDs inhibit prostate cancer cell motility and osteoclast mediated bone destruction in vitro . Our lead compound, BTE-EN1, inhibits circulating human prostate cancer cells from forming bone destructive lesions in mice and prolongs life in a dose-dependent fashion. In mice with established metastatic lesions, BTE-EN1 significantly decreases bone destruction by over 60% compared to the control. Mechanistically, BTE-EN1 binds hydroxyapatite, inhibits prenylation of Rap1A, induces apoptosis in osteoclasts, and inhibits Raf1 activation and formation of bone resorptive cavities in osteoclasts, thus retaining the function of its constituent chemicals. BTE-EN1 is not toxic to mice at doses 4,000-fold over those required for efficacy, exhibits anti-cell motility activity across other bone-destructive cancer cell types, and does not interfere with standard-of-care hormone therapy or chemotherapy. BTE-EN1 is a new class of highly active therapeutics that inhibit cancer mediated bone destruction and holds high potential for translation into humans.
BibTeX
@misc{qiao2025new,
  author = {Fangfang Qiao and Ryan R. Gordon and Abhinandan Pattanayak and Wenqi Li and Jaclyn Knibbe-Hollinger and Katelyn O’Neill and Weining Chen and Prathap Reddy Mukthapuram and Amarnath Natarajan and Raymond C. Bergan},
  title = {{A New Class of Precision Therapeutics that Inhibit Prostate Cancer Mediated Bone Destruction}},
  year = {2025},
  doi = {10.1101/2025.05.20.654990},
  howpublished = {bioRxiv},
}
Figure